Factor VII (F.VII, Stable Factor, Proconvertin)

Factor VII (F.VII, also known as Stable Factor and Proconvertin) is a vitamin K-dependent glycoprotein produced in the liver. Plasma concentration of F.VII is normally ~0.5ug/ml (10nM) in plasma. A deficiency of F.VII is associated with bleeding in a clinical pattern similar to haemophilia, but is inherited as an autosomal recessive trait. The deficiency can be characterized by a quantitative (low activity and low antigen) or a qualitative (low activity and normal antigen) defect in F.VII function. In its zymogen form F.VII is a single chain molecule of ~50kD. It contains two EGF-like domains and an amino-terminal domain containing 10 g-carboxyglutamic acid (Gla) residues. These Gla residues allow F.VII to bind divalent metal ions and participate in calcium-dependent binding interactions. F.VII and activated F.VII (F.VIIa) bind to tissue factor exposed at the site of vascular injury. F.IXa, F.Xa or F.VIIa rapidly activate tissue factorbound F.VII to F.VIIa in the presence of calcium and phospholipid. Thrombin and F.XIIa are able to activate F.VII in the fluid phase in the absence of cofactors. The activation of the single chain zymogen F.VII occurs by proteolysis after residue Arg152, resulting in a two chain active serine protease consisting of a 30kD heavy chain and an 18kD light chain. In complex with tissue factor, phospholipids and calcium, F.VIIa is able to activate F.X and F.IX. Free F.VIIa in plasma is remarkably stable, but the activity of F.VIIa/TF complex is regulated by Tissue Factor Pathway Inhibitor (TFPI) in the presence of F.Xa, and also by Antithrombin (ATIII) in the presence of heparin1-3.\n\nApplication:\nSuitable for use in Immunodepletion Procedures and Neutralization Studies. Other applications not tested.\n\nRecommended Dilutions:\nOptimal dilutions to be determined by the researcher.\n\nStorage and Stability:\nMay be stored at 4 degrees C for short-term only. For long-term storage, store at -20 degrees C. Aliquots are stable for at least 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

F0015-20A

Size

1mg

Applications

IP

Hosts

Sheep

Reactivities

Hum

Form

Supplied in HEPES-buffered saline, pH 7.4, 50% glycerol. No preservatives are added.

P Type

Pab

Purity

Purified by caprylic acid and ammonium sulfate precipitations, and solid -phase adsorption to remove unwanted crossreactivity.

Isotype

IgG

References

1. Rao, L.V.M., Bajaj, S.P., Rapaport, S.I., Activation of Human Factor VII During Clotting in Vitro. Blood 65: 218-226 (1985). 2. Lawson, J.H., Butenas, S., Ribarik, N., Mann, K.G., Complex-dependent Inhibition of Factor VIIa by Antithrombin III and Heparin. JBC 268: 767-770 (1993). 3. Nemerson, Y., in Hemostasis and Thrombosis, 3rd Edition, eds. R.W. Colman, J. Hirsh, V.J. Marder, E.W. Salzman, pp. 81-93, J.B. Lippincott Co., Philadelphia PA, USA (1994).

Additional Info

It is specific for F.VII as determined by immunodiffusion. Identity was established with purified F.VII.